Single gland excision for MEN1‐associated primary hyperparathyroidism. (12th November 2019)

• Record Type: Journal Article
• Authors: Manoharan, Jerena; Albers, Max B.; Bollmann, Carmen; Maurer, Elisabeth; Mintziras, Ioannis; Wächter, Sabine; Bartsch, Detlef K.
• Is Part Of: Clinical endocrinology. Volume 92:Number 1(2020)
• Page Start: 63
• Page End: 70
• Publication Date: 2019-11-12
• Subjects: hypocalcemia -- hypoparathyroidism -- laryngeal nerve palsy -- multiple endocrine neoplasia type 1 -- primary hyperparathyroidism -- recurrence -- surgery; Endocrinology -- Periodicals; 616.4005
• DOI: 10.1111/cen.14112
• Languages: English
• ISSNs: 0300-0664

Abstract

Abstract: Importance: Guidelines advocate subtotal parathyroidectomy (SPTX) or total parathyroidectomy with autotransplantation (TPTX) with bilateral cervical thymectomy for primary hyperparathyroidism (pHPT) associated with multiple endocrine neoplasia type 1 (MEN1). However, both procedures are associated with a significant risk of permanent hypoparathyroidism. Objective: The aim of the current study was to compare long‐term results of either single gland excision (SGE, 1‐2 glands), SPTX and TPTX for the treatment of MEN1‐associated pHPT. Design and setting: Data of genetically confirmed MEN1 patients who underwent surgery for pHPT between 1987 and 2017 were retrieved from a prospective database and were retrospectively analysed. Results: Eighty‐nine MEN1 patients underwent either TPTX (n = 38, 42.7%), SPTX (n = 23, 25.8%) or SGE (n = 28, 31.5%). The rate of disease persistence after initial surgery was 2.6%, 0% and 14.2% in the TPTX, SPTX and SGE groups, respectively. After median follow‐up of 112 (range 7‐411) months, the rate of recurrent pHPT was significantly higher in the SGE group (n = 19, 21.3%) compared with the TPTX (n = 4, 4.4%, P = .001) and the SPTX (n = 9, 10.1%, P = .03) groups. Analysis of the recurrence‐free time among the surgical groups revealed a significant difference ( P = .036). The median time to recurrence was significantly shorter after SGE (101, range 3‐301 months) than after SPTX (139, range 28‐278 months, P = .018) and TPTX (204, range 75‐396 months, P = .049). Twelve (32%) patients who underwent TPTX developed permanent hypoparathyroidism compared with only 4 (17%, P = .06) in the SPTX and 0 in the SGE group ( P = .001). Conclusion: Given the high rate of postoperative permanent hypoparathyroidism after TPTX and SPTX, SGE is a valid option for the treatment of MEN1‐associated pHPT.